56R0.F Stock Analysis
56
Uncovered
Nanovibronix Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Elmsford, New York and currently employs 12 full-time employees. The company went IPO on 2015-04-24. The firm is focused on developing noninvasive biological response-activating devices utilizing its low intensity surface acoustic wave (SAW) technology, which targets biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products, which are in various stages of clinical and market development consist of UroShield, PainShield and WoundShield. Its UroShield is an ultrasound-based product that prevents bacterial colonization and biofilm in urinary catheters. Its PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures. Its PainShield family of products include PainShield MD, PainShield Plus and PainShield Relief. WoundShield is a patch-based therapeutic ultrasound device developed to facilitate tissue regeneration and wound healing. Its wholly owned subsidiary is NanoVibronix Ltd.